



Result of Annual General Meeting

October 27, 2016

Released : October 27, 2016 07:00

RNS Number : 5694N

MaxCyte, Inc.

27 October 2016

MaxCyte, Inc.
("MaxCyte" or the "Company")

Result of Annual General Meeting

Maryland, USA - 27 October 2016: MaxCyte (LSE: MXCT), the revenue-generating developer of next generation cell-based medicines, products and services, announces that at its Annual General Meeting held yesterday at 22 Firstfield Road, Suite 110, Gaithersburg, MD 20878 USA, all resolutions were duly passed.

- ENDS -

For further information please contact:

MaxCyte

+1 301 944 1660

Doug Doerfler, Chief Executive Officer

Ron Holtz, Chief Financial Officer

Nominated Adviser and Broker

+44 (0) 20 7886 2500

Panmure Gordon

Freddy Crossley (Corporate Finance)

Fabien Holler

Duncan Monteith

Tom Salvesen (Corporate Broking)

Financial PR Advisor

Consilium Strategic Communications

+44 (0)203 709 5700

maxcyte@consilium-comms.com

Mary-Jane Elliott

Chris Welsh

Lindsey Neville

About MaxCyte

MaxCyte is an established and revenue generating US-based developer and supplier of cell engineering products and services to biopharmaceutical firms engaged in cell therapy, drug discovery and development, biomanufacturing, gene editing and immuno-oncology markets, which independent market analyses estimate to be, in aggregate, in excess of \$35 billion in 2015. The Company's patented flow electroporation technology enables its products to deliver fast, reliable and scalable cell engineering to drive the research and clinical development of a new generation of medicines.

MaxCyte's high performance platform allows transfection with any molecule or multiple molecules and is compatible with nearly all cell types, including hard-to-transfect human primary cells. It also provides a high degree of consistency and minimal cell disturbance, thereby facilitating rapid, large scale, clinical and commercial grade cell engineering in a non-viral system and with low toxicity concerns. The Company's cell engineering technology platform is CE-marked and FDA-accredited, providing MaxCyte's customers and partners with an established regulatory path.

Using the unique capabilities of its technology, MaxCyte is developing CARMA, its proprietary platform in immuno-oncology, to deliver a validated non-viral approach to CAR therapies across a broad range of cancer indications, including solid tumors where existing CAR-T approaches face significant challenges.

For more information visit <http://www.maxcyte.com/>

This information is provided by RNS
The company news service from the London Stock Exchange

END

RAGLQLLQBFLFBV